Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCPVax +/- Pembrolizumab Combined With Standard Treatment in Unmethylated MGMT Glioblastoma
NCT07347210Phase 2Not yet recruiting
- Sponsor
- CHU de Besançon
- Start
- Jan 2026
- Primary completion
- Jan 2029
- Modality
- Peptides, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of UCPVax in glioblastoma (GBM), sponsored by CHU de Besançon. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
UCPVax
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07347210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07347210.